Olema Oncology is a clinical-stage biopharmaceutical company based in San Francisco that develops targeted small-molecule therapies for ER+/HER2- metastatic breast cancer and other women's cancers. Its lead candidate, palazestrant (OP-1250), is an oral complete estrogen receptor antagonist and selective ER degrader now in two Phase 3 trials, while a second program, OP-3136, is a KAT6 inhibitor in Phase 1. Olema's bet is that better-designed oral endocrine therapy can overcome the resistance that limits today's standard of care.
Sean P. Bohen is President and CEO of Olema Oncology, a San Francisco clinical-stage biopharmaceutical company developing targeted therapies for women's cancers. An MD/PhD oncologist who spent 13 years at Genentech and four as AstraZeneca's Chief Medical Officer, he is now steering Olema's lead drug palazestrant - an oral complete estrogen receptor antagonist - through Phase 3 trials in ER+/HER2- metastatic breast cancer.